Patterns in anticoagulant utilization in the Czech Republic during 2007-2017
Jazyk angličtina Země Nizozemsko Médium print
Typ dokumentu časopisecké články
PubMed
30659407
DOI
10.1007/s11239-019-01806-z
PII: 10.1007/s11239-019-01806-z
Knihovny.cz E-zdroje
- Klíčová slova
- Anticoagulants, Czech Republic, DOAC, Drug utilization, Warfarin,
- MeSH
- antikoagulancia aplikace a dávkování ekonomika MeSH
- aplikace orální MeSH
- časové faktory MeSH
- databáze faktografické MeSH
- hodnocení spotřeby léčiv trendy MeSH
- lékařská praxe - způsoby provádění ekonomika trendy MeSH
- lékové předpisy MeSH
- lidé MeSH
- náklady na léky trendy MeSH
- retrospektivní studie MeSH
- výdaje na zdravotnictví trendy MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- antikoagulancia MeSH
Direct oral anticoagulants (DOACs) have gradually entered the Czech market as alternatives to vitamin K antagonists and parenteral anticoagulants since 2008. Considering the eventual changes, the aim was to evaluate drug use and expenditure patterns on anticoagulants in the Czech Republic. A retrospective utilization study was conducted retrieving data from the State Institute for Drug Control database, including reports on drug supplies from distributors with anatomical therapeutic chemical classification (ATC) codes B01AA, B01AB, B01AE, B01AF, and B01AX. The utilization on national level was expressed as the ratio of the number of defined daily doses per 1000 inhabitants per day (DDD/TID). Expenditures on all anticoagulants were also assessed. Data was analyzed using PASW (version 18.0). Between January 2007 and December 2017, the national anticoagulant utilization rate increased continuously from 14.15 to 27.67 DDD/TID. The use of DOACs was 0.002 DDD/TID in 2008, increased to 6.04 DDD/TID in 2017. Warfarin utilization, after a small decrease in 2008, has shown nearly stable levels in the recent years (70.9% of all anticoagulants; mean 11.55 DDD/TID over the last 5 years), while its increase was halted by the spread of DOACs utilization (p < 0.05). In 2017, over half of the expenditures (51.1%) were due to oral anticoagulants, whereof 47.6% was related to DOACs. The results reflected a growing utilization and increasing costs of all anticoagulants, especially in DOACs at the expense of warfarin. Still, additional information regarding patient persistence and prescribing patterns is needed for a better understanding of oral anticoagulant utilization.
Zobrazit více v PubMed
Semin Hematol. 2002 Jul;39(3):172-8 PubMed
Pharmacotherapy. 2004 Oct;24(10 Pt 2):199S-202S PubMed
Eur J Clin Invest. 2005 Mar;35 Suppl 1:27-32 PubMed
N Engl J Med. 2009 Sep 17;361(12):1139-51 PubMed
Lancet. 2012 May 12;379(9828):1835-46 PubMed
Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):615-21 PubMed
Curr Emerg Hosp Med Rep. 2013 Apr 21;1(2):83-97 PubMed
Pharmacoeconomics. 2014 Sep;32(9):919-36 PubMed
CMAJ Open. 2013 Oct 16;1(3):E115-9 PubMed
Europace. 2015 Feb;17(2):187-93 PubMed
Circulation. 2015 Jan 13;131(2):157-64 PubMed
Am J Med. 2015 Dec;128(12):1300-5.e2 PubMed
Int J Clin Pharm. 2015 Dec;37(6):1128-35 PubMed
Europace. 2015 Oct;17(10):1467-507 PubMed
BMJ Case Rep. 2015 Oct 09;2015:null PubMed
Clin Ther. 2015 Nov 1;37(11):2506-2514.e4 PubMed
Expert Opin Pharmacother. 2016;17(4):535-43 PubMed
Drugs Aging. 2016 Jul;33(7):491-500 PubMed
Lancet. 2017 Dec 17;388(10063):3060-3073 PubMed
Eur Heart J. 2016 Oct 7;37(38):2893-2962 PubMed
CJEM. 2016 Sep;18(5):340-8 PubMed
J Clin Pharm Ther. 2017 Apr;42(2):132-134 PubMed
J Thromb Thrombolysis. 2017 Apr;43(3):411-416 PubMed
Br J Clin Pharmacol. 2017 Sep;83(9):2096-2106 PubMed
Vnitr Lek. 2017 Fall;63(10):633-639 PubMed
Int J Clin Pharm. 2017 Dec;39(6):1282-1290 PubMed
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):174-181 PubMed
BMJ. 2017 Nov 28;359:j5058 PubMed
J Thromb Thrombolysis. 2018 Aug;46(2):139-144 PubMed
